CliffBio
small molecule

JYNARQUE

TOLVAPTAN

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameJYNARQUE
Active ingredientTOLVAPTAN
Strength15MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusRX

Listed patents

PatentExpiresType
10905694April 2030product
8501730September 2026substance

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JYNARQUE patent cliff — loss of exclusivity April 2030 | CliffBio